Specific recognition of natural targets by the FMNL1-PP2–specific T-cell clone. The FMNL1-PP2–specific T-cell clone was tested against the HLA-A2⁺ lymphoma cell lines BJ18 and DG75; the HLA-A2⁻ lymphoma cell line Raji; the HLA-A2⁺ renal cell carcinoma cell line RCC26; the HLA-A2⁻ renal cell carcinoma cell line KT187 (A); and HLA-A2⁺ EBV-transformed cell lines (B), in a ⁵¹Cr-release assay at an effector-target ratio of 7.5:1. Error bars indicate the standard deviation of tested duplicates. Results shown are representative of at least 3 experiments. (C) IFN-γ release was investigated by ELISA to test the FMNL1-PP2–specific T-cell clone against CD40L-activated CLL cells (HLA-A2⁺ and HLA-A2⁻) at an effector-target ratio of 1:2. Error bars indicate the standard deviation of tested triplicates. (D) PBMCs (HLA-A2⁺ and HLA-A2⁻) activated with IL-2 and OKT3, CD19⁺ B cells (HLA-A2⁺ and HLA-A2⁻) stimulated with CD40L, as well as HLA-A2⁺ lung fibroblasts and HLA-A2⁺ embryonal kidney cells (293 HEK) were used as target cells for the FMNL1-PP2–specific T-cell clone in a ⁵¹Cr-release assay at an effector-target ratio of 7.5:1. Error bars indicate the standard deviation of tested duplicates. Results shown are representative of 5 experiments.